BR112012028091A2 - composições farmacêuticas compreendendo pioglitazona e linagliptina - Google Patents
composições farmacêuticas compreendendo pioglitazona e linagliptinaInfo
- Publication number
- BR112012028091A2 BR112012028091A2 BR112012028091A BR112012028091A BR112012028091A2 BR 112012028091 A2 BR112012028091 A2 BR 112012028091A2 BR 112012028091 A BR112012028091 A BR 112012028091A BR 112012028091 A BR112012028091 A BR 112012028091A BR 112012028091 A2 BR112012028091 A2 BR 112012028091A2
- Authority
- BR
- Brazil
- Prior art keywords
- pioglitazone
- pharmaceutical compositions
- linagliptin
- dpp
- processes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
composições farmacêuticas compreendendo pioglitazona e linagliptina. a presente invençõa refere-se, a composição farmacêuticas compreendendo combinações de doses fixas de um fármaco inibidor da dpp-4 e pioglitazona, processos para a preparação do mesmo, e sua aplicação para tratar algumas doenças.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10162067 | 2010-05-05 | ||
EP11164203 | 2011-04-28 | ||
PCT/EP2011/057163 WO2011138380A1 (en) | 2010-05-05 | 2011-05-04 | Pharmaceutical formulations comprising pioglitazone and linagliptin |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012028091A2 true BR112012028091A2 (pt) | 2016-08-02 |
Family
ID=44123523
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012028091A BR112012028091A2 (pt) | 2010-05-05 | 2011-05-04 | composições farmacêuticas compreendendo pioglitazona e linagliptina |
Country Status (16)
Country | Link |
---|---|
US (2) | US20120107398A1 (pt) |
EP (1) | EP2566464A1 (pt) |
JP (1) | JP5826830B2 (pt) |
KR (1) | KR20130069615A (pt) |
CN (1) | CN102883711A (pt) |
AR (1) | AR082091A1 (pt) |
AU (1) | AU2011249771A1 (pt) |
BR (1) | BR112012028091A2 (pt) |
CA (1) | CA2795105A1 (pt) |
CL (1) | CL2012003026A1 (pt) |
EA (1) | EA201201509A1 (pt) |
MX (1) | MX2012012438A (pt) |
NZ (1) | NZ602809A (pt) |
TW (1) | TW201206917A (pt) |
UY (1) | UY33370A (pt) |
WO (1) | WO2011138380A1 (pt) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
KR101541791B1 (ko) | 2006-05-04 | 2015-08-04 | 베링거 인겔하임 인터내셔날 게엠베하 | 다형태 |
CL2008002427A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2. |
PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
AU2009290911A1 (en) | 2008-09-10 | 2010-03-18 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
NZ592924A (en) | 2008-12-23 | 2014-05-30 | Boehringer Ingelheim Int | Salt forms of a xanthine derivative |
TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
SI2395983T1 (sl) | 2009-02-13 | 2020-08-31 | Boehringer Ingelheim International Gmbh | Farmacevtski sestavek, ki obsega SGLT2 inhibitor, DPP-IV inhibitor in po izbiri nadaljnje antidiabetično sredstvo in uporabe le-teh |
CA2782179C (en) | 2009-11-27 | 2020-06-23 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
NZ602921A (en) | 2010-05-05 | 2016-01-29 | Boehringer Ingelheim Int | Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor |
JP5843855B2 (ja) | 2010-06-24 | 2016-01-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病療法 |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
UY33937A (es) | 2011-03-07 | 2012-09-28 | Boehringer Ingelheim Int | Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina |
ES2713566T3 (es) | 2011-07-15 | 2019-05-22 | Boehringer Ingelheim Int | Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II |
WO2013055609A1 (en) * | 2011-10-12 | 2013-04-18 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions that inhibit disproportionation |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
EP3685839A1 (en) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin for use in the treatment of albuminuria and kidney related diseases |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
EP3311803A1 (en) * | 2012-08-13 | 2018-04-25 | Sandoz AG | Stable pharmaceutical composition containing 8-[(3r)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1h-purine-2,6-dione or a pharmaceutically acceptable salt thereof |
WO2014080384A1 (en) * | 2012-11-26 | 2014-05-30 | Ranbaxy Laboratories Limited | Pharmaceutical composition of linagliptin |
TR201310724A2 (tr) * | 2013-09-12 | 2015-03-23 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Linagliptinin farmasotik formulasyonları. |
ES2950384T3 (es) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Uso médico de un inhibidor de DPP-4 |
US20150283248A1 (en) * | 2014-04-02 | 2015-10-08 | Aurobindo Pharma Ltd. | Pharmaceutical compositions of Linagliptin and process for preparation thereof |
CN105456270B (zh) * | 2014-08-27 | 2021-03-16 | 石药集团中奇制药技术(石家庄)有限公司 | 一种二肽基肽酶ⅳ抑制剂药物组合物、其用途及其制备方法 |
US11096945B2 (en) * | 2015-03-31 | 2021-08-24 | Aurobindo Pharma Ltd | Pharmaceutical compositions of linagliptin and process for preparation thereof |
CN109310697A (zh) | 2016-06-10 | 2019-02-05 | 勃林格殷格翰国际有限公司 | 利格列汀和二甲双胍的组合 |
KR102500835B1 (ko) * | 2017-10-24 | 2023-02-17 | 한미약품 주식회사 | 리나글립틴 및 메트포르민을 포함하는 복합제제 및 그의 제조방법 |
CN108524460B (zh) * | 2018-05-14 | 2021-01-01 | 佛山市南海东方澳龙制药有限公司 | 烯啶虫胺双层片 |
KR20210045404A (ko) * | 2018-08-02 | 2021-04-26 | 오스피탈 산트 호안 데 데우 | 다낭성 난소 증후군 치료에 유용한 활성 약학적 성분들의 삼중 조합의 즉시 방출 제제 |
EP4385501A1 (en) * | 2022-12-15 | 2024-06-19 | Sanovel Ilac Sanayi Ve Ticaret A.S. | A pharmaceutical formulation comprising linagliptin, pioglitazone and a sglt-2 inhibitor |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9109862D0 (en) * | 1991-05-08 | 1991-07-03 | Beecham Lab Sa | Pharmaceutical formulations |
EE05735B1 (et) | 2001-02-24 | 2015-01-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ksantiini derivaadid, nende valmistamine ja kasutamine ravimina |
AU2002337749A1 (en) | 2001-09-28 | 2003-04-07 | Teva Pharmaceutical Industries Ltd. | Pioglitazone hydrochloride |
UA84275C2 (ru) | 2002-08-21 | 2008-10-10 | Бёрингер Ингельхайм Фарма Гмбх & Ко. Кг | 8-[3-аминопиперидин-1-ил]ксантины, способ их получения и их применение как лекарственных средств |
DE10238470A1 (de) | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
DE10238477A1 (de) | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
DE10251927A1 (de) | 2002-11-08 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
DE10254304A1 (de) | 2002-11-21 | 2004-06-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
UY28103A1 (es) | 2002-12-03 | 2004-06-30 | Boehringer Ingelheim Pharma | Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos |
DE10327439A1 (de) | 2003-06-18 | 2005-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel |
DE10355304A1 (de) | 2003-11-27 | 2005-06-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
DE10359098A1 (de) | 2003-12-17 | 2005-07-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-(Piperazin-1-yl)- und 2-([1,4]Diazepan-1-yl)-imidazo[4,5-d]pyridazin-4-one, deren Herstellung und deren Verwendung als Arzneimittel |
DE10360835A1 (de) | 2003-12-23 | 2005-07-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel |
AU2005219508B2 (en) | 2004-02-18 | 2012-02-16 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthine, the production thereof and the use in the form of a DPP inhibitor |
DE102004009039A1 (de) | 2004-02-23 | 2005-09-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel |
JP2007531780A (ja) | 2004-04-10 | 2007-11-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規な2−アミノ−イミダゾ[4,5−d]ピリダジン−4−オン及び2−アミノ−イミダゾ[4,5−c]ピリダジン−4−オン、その製法及び医薬としての使用 |
DE102004043944A1 (de) | 2004-09-11 | 2006-03-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
DE102004044221A1 (de) | 2004-09-14 | 2006-03-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
KR20070068407A (ko) * | 2004-10-25 | 2007-06-29 | 노파르티스 아게 | Dpp―iv 억제제, ppar 항당뇨병제 및메트포르민의 조합물 |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
CA2590912A1 (en) | 2004-12-24 | 2006-06-29 | Dainippon Sumitomo Pharma Co., Ltd. | Bicyclic pyrrole derivatives |
GT200600218A (es) * | 2005-06-10 | 2007-03-28 | Formulación y proceso de compresión directa | |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
US20090192138A1 (en) | 2005-12-23 | 2009-07-30 | Daniel Kaspar Baeschlin | compounds |
KR101541791B1 (ko) | 2006-05-04 | 2015-08-04 | 베링거 인겔하임 인터내셔날 게엠베하 | 다형태 |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
EP2057160A1 (en) | 2006-08-08 | 2009-05-13 | Boehringer Ingelheim International GmbH | Pyrrolo [3, 2 -d]pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus |
DK2107905T3 (da) * | 2007-02-01 | 2011-01-31 | Takeda Pharmaceutical | Fast sammensætning omfattende alogliptin og pioglitazon |
US20090186086A1 (en) * | 2008-01-17 | 2009-07-23 | Par Pharmaceutical, Inc. | Solid multilayer oral dosage forms |
PE20140960A1 (es) * | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
UY32177A (es) * | 2008-10-16 | 2010-05-31 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético |
JP2012517977A (ja) * | 2009-02-13 | 2012-08-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Dpp−4阻害剤(リナグリプチン)を任意で他の抗糖尿病薬と組み合わせて含む抗糖尿病薬 |
SI2395983T1 (sl) * | 2009-02-13 | 2020-08-31 | Boehringer Ingelheim International Gmbh | Farmacevtski sestavek, ki obsega SGLT2 inhibitor, DPP-IV inhibitor in po izbiri nadaljnje antidiabetično sredstvo in uporabe le-teh |
EP2442806A1 (en) * | 2009-06-15 | 2012-04-25 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone |
EP4209210A1 (en) * | 2009-10-02 | 2023-07-12 | Boehringer Ingelheim International GmbH | Pharmaceutical compositions comprising bi-1356 and metformin |
-
2011
- 2011-05-04 KR KR1020127028888A patent/KR20130069615A/ko not_active Application Discontinuation
- 2011-05-04 AU AU2011249771A patent/AU2011249771A1/en not_active Abandoned
- 2011-05-04 CA CA2795105A patent/CA2795105A1/en not_active Abandoned
- 2011-05-04 NZ NZ602809A patent/NZ602809A/en not_active IP Right Cessation
- 2011-05-04 BR BR112012028091A patent/BR112012028091A2/pt not_active IP Right Cessation
- 2011-05-04 MX MX2012012438A patent/MX2012012438A/es not_active Application Discontinuation
- 2011-05-04 WO PCT/EP2011/057163 patent/WO2011138380A1/en active Application Filing
- 2011-05-04 EA EA201201509A patent/EA201201509A1/ru unknown
- 2011-05-04 CN CN2011800222425A patent/CN102883711A/zh active Pending
- 2011-05-04 TW TW100115645A patent/TW201206917A/zh unknown
- 2011-05-04 AR ARP110101545A patent/AR082091A1/es unknown
- 2011-05-04 US US13/100,328 patent/US20120107398A1/en not_active Abandoned
- 2011-05-04 JP JP2013508493A patent/JP5826830B2/ja active Active
- 2011-05-04 EP EP11720070A patent/EP2566464A1/en not_active Withdrawn
- 2011-05-05 UY UY0001033370A patent/UY33370A/es not_active Application Discontinuation
-
2012
- 2012-10-29 CL CL2012003026A patent/CL2012003026A1/es unknown
-
2013
- 2013-11-22 US US14/087,388 patent/US20140079781A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20130069615A (ko) | 2013-06-26 |
CL2012003026A1 (es) | 2013-02-01 |
UY33370A (es) | 2011-12-30 |
US20140079781A1 (en) | 2014-03-20 |
US20120107398A1 (en) | 2012-05-03 |
JP2013525468A (ja) | 2013-06-20 |
JP5826830B2 (ja) | 2015-12-02 |
EP2566464A1 (en) | 2013-03-13 |
CA2795105A1 (en) | 2011-11-10 |
NZ602809A (en) | 2015-02-27 |
WO2011138380A1 (en) | 2011-11-10 |
AR082091A1 (es) | 2012-11-14 |
MX2012012438A (es) | 2012-11-29 |
EA201201509A1 (ru) | 2013-04-30 |
CN102883711A (zh) | 2013-01-16 |
AU2011249771A1 (en) | 2012-11-01 |
TW201206917A (en) | 2012-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012028091A2 (pt) | composições farmacêuticas compreendendo pioglitazona e linagliptina | |
BR112013022789A2 (pt) | composições farmacêuticas que compreendem metformina e um inibidor dpp-4 ou um inibidor sglt-2 | |
PH12014501984A1 (en) | Pharmaceutical compositions comprising metformin and a dpp-4 inhibitor or a sglt-2 inhibitor | |
CY1124928T1 (el) | Αναστολεις πυραζολυλο κινοξαλινο κινασης | |
ECSP12011834A (es) | Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, métodos para su tratamiento y sus usos. | |
MA32200B1 (fr) | Nouvelles formulations,comprimes comprenant de telles formulations, leur utilisation et leur procede de preparation | |
PH12017501306A1 (en) | Inhibitors of histone demethylases | |
CR20120419A (es) | Formulación de anticuerpos y regimenes terapéuticos | |
GB201118656D0 (en) | New compounds | |
EA201200937A1 (ru) | Твердая лекарственная форма тикагрелора | |
BR112012030704A2 (pt) | composições farmacêuticas de cocristais de tramadol e coxibs | |
CU20140037A7 (es) | Derivados de estra- 1,3,5(10), 16- tetraen- 3- carboximida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos | |
UY33530A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias | |
ES2429422R1 (es) | Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH | |
BRPI0606322A2 (pt) | formulações intravenosas de inibidores de pde-5 | |
UY33723A (es) | ?COMPUESTOS Y SU USO PARA TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON Aß?. | |
BR102012028120B8 (pt) | Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento | |
EA201490417A1 (ru) | Новые легкоразрушающиеся ингибиторы pde 4 | |
BR112016007031A8 (pt) | composição farmacêutica oral sólida, processo para preparar a composição farmacêutica oral sólida, e uso de uma composição farcêutica oral sólida | |
PE20160520A1 (es) | Composicion farmaceutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende granulos de isoniazid y granulos de rifapentina y su proceso de preparacion | |
TN2010000431A1 (en) | New formulations, tablets comprising such formulations, their use and process for their preparation | |
SA515360233B1 (ar) | مثبطات إنزيمات هستون ديميثيلاز | |
NI201200162A (es) | Inhibidores de pirazolil quinoxalina cinasa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2386 DE 27-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |